< Back

PolyPid Announces Presentation of D-PLEX₁₀₀ Phase 2 Clinical Data at ASM Microbe 2022

June 6, 2022 at 7:00 AM EDT

Phase 2 clinical data on the efficacy of D-PLEX100 in surgical site infection prevention in elective colorectal surgery will be presented during a poster presentation

PETACH TIKVA, Israel, June 06, 2022 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, announced today that data from a previously completed Phase 2 clinical trial of D-PLEX100 will be highlighted in a presentation at the upcoming American Microbiology Society (ASM) Microbe 2022, being held on June 9-13, 2022, in Washington, D.C.

The abstract, ‘Incisional microenvironments and reduction in SSIs in patients treated with a local doxycycline-eluting formulation, evaluates the effect of D-PLEX100 in combination with surgical site infection standard of care prophylaxis regimen in elective colorectal surgery. The data will be presented by Judith Steenbergen, Ph.D., President of Scientific and Medical Affairs Consulting (SMAC). The abstract will be available on https://www.polypid.com/ following the presentation.

About PolyPid

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trials for the prevention of soft tissue abdominal and sternal bone surgical site infections. In addition, the company is currently in preclinical stages to test the efficacy of OncoPLEX for treatment of solid tumors, beginning with glioblastoma. For additional company information, please visit http://www.polypid.com and follow us on Twitter and LinkedIn.

References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. PolyPid is not responsible for the contents of third-party websites.

Corporate Contact:

PolyPid Ltd.
Dikla Czaczkes Akselbrad
Tel: +972-747195700

Investor Contact:
Bob Yedid
LifeSci Advisors

Media Contact:
Nechama Feuerstein
FINN Partners


Primary Logo

Source: PolyPid Ltd.


PolyPid’s PLEX targeted drug delivery platform enables localized, controlled, continuous release of medication over prolonged periods of time for better patient outcomes.

Read More >


Provides safe and effective local antibiotic protection against SSI (surgical Site Infection) at the needed tissues or organs by administration during surgical procedures.

Read More >


Comprised of antibiotic eluting ß tri-calcium phosphate (ßTCP) granules, designed for bone related infections applications.

Read More >